Investment Date
February 2019
Outsourced Services, MedTech
Corporate HQ
North Carolina, US

BioAgilytix provides large molecule bioanalysis services, partnering with many of the world’s top pharmaceutical and biotech companies.

BioAgilytix’s services include the development and validation of biomarker, immunogenicity, pharmacokinetic and cell-based assays to support clinical trials in large and fast-growing areas of drug development such as biosimilars, immuno-oncology, and gene and cell therapy.

GHO value creation

Enablement & Alignment

  • Shared vision to create a global leader in the large molecule industry. A global platform, destination employer and maintaining an industry leading customer service rating
  • Focus on science-led approach with best-of-breed expertise and capabilities to support all phases of large molecule global studies. Quality Excellence as #1 priority

Capability & Capacity

  • Significant investments in building out the team and upskilling global business functions (operations, finance, BD, scientific bench)
  • Adding new capabilities in cell & gene therapy, biosimilars, antibody drug conjugates, immune-oncology and orphan diseases

Building Strategic Footprints

  • Organic and inorganic investment in laboratory facilities (including CAP & CLIA accreditations), scientific and technological expertise (CAR-T, PCR and Flow Cytometry) and commercial footprint
  • Physical presence in Boston to access high concentration of biotech firms
  • Focus on significant European expansion, leveraging successful market entry in Germany. Move to penetrate Asian markets

Better, faster + more accessible healthcare

GHO realises investment in BioAgilytix to Cinven

Subscribe to our email alerts

Email updates